TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01682746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photofrin (porfimer sodium) & photodynamic therapy.
Description: Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time.
Study: NCT01634451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation specific outcome process feedback
Description: Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Responsiveness monitoring; novel sedation monitor
Description: Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Responsiveness monitoring; novel sedation monitor
Description: Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
Study: NCT04610502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of Equine immunoglobulin anti SARS-CoV-2
Description: The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of Equine immunoglobulin anti SARS-CoV-2
Description: The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
Study: NCT03623971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract AI agent
Description: An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
Study: NCT01132300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)
Description: Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
Study: NCT02278965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850mg, oral, twice a day for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
Study: NCT04222842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082
Description: Subjects will receive CM082 orally for two weeks followed by two weeks off in four-week cycles.The total treatment period is tentatively set at 3 cycles (12 weeks).
Study: NCT01633099

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: 1. Number of Cycles: 4 cycles.~2. Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,\>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells\<5%, the following cycle:decitabine 20 mg/m2, (iv,\>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,\>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,\>1h, on d1-3 of each 28day cycle).
Study: NCT06040216

Intervention type: OTHER
Intervention: optical coherence tomography
Description: We observed the postoperative improvement in EIFL severity with optical coherence tomography

Intervention type: OTHER
Intervention: optical coherence tomography
Description: We observed the postoperative improvement in EIFL severity with optical coherence tomography

Intervention type: OTHER
Intervention: optical coherence tomography
Description: We observed the postoperative improvement in EIFL severity with optical coherence tomography
Study: NCT02944435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839 Capsules
Description: 3 x 200 mg CB-839 Capsules (Reference Formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CB-839 Tablets
Description: 3 x 200 mg CB-839 Tablets (Test Formulation)
Study: NCT01825239

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of measurements during LV pacing during electrophysiology study
Description: During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
Study: NCT03877224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
Study: NCT01589679

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metarsal Dynasplint
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
Study: NCT02456961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iontophoresis of riboflavin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epithelium-off

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal collagen crosslinking
Description: Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking
Description: Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galvanizator, Potok-1
Description: Device for providing iontophoresis procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextralink
Description: Riboflavin 0,1% + Dextran T-500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 0,1%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UFalink
Description: device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
Study: NCT04053569

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Table Grape supplement
Description: 5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
Study: NCT02456961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UFalink
Description: device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
Study: NCT03541707

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep TMS Brainsway's H coil
Description: During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep TMS Brainsway's H coil
Description: During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes.
Study: NCT02751164

Intervention type: OTHER
Intervention: Day/time of admission to the critical care unit

Intervention type: OTHER
Intervention: Day/time of admission to the critical care unit

Intervention type: OTHER
Intervention: Day/time of admission to the critical care unit

Intervention type: OTHER
Intervention: Day/time of admission to the critical care unit
Study: NCT02411981

Intervention type: OTHER
Group type: OTHER
Intervention: Autogenic drainage
Study: NCT04588844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Recombinant Human Somatropin
Description: Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
Study: NCT00110799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB497115
Description: Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB497115
Description: Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB497115
Description: Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
Study: NCT00827658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Wrist Block
Description: Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothenar Palm block
Description: Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)
Study: NCT01995864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTI-TS
Description: The following briefly describes the three phases of CTI-TS:~Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.~Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.~Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual.
Study: NCT03932929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive (3M ESPE)
Description: Adhesive system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive (3M ESPE)
Description: Adhesive system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive (3M ESPE)
Description: Adhesive system
Study: NCT01990872

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (20 micrograms/day)
Description: Vitamin D3 (20 micrograms/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (20 micrograms/day)
Description: Vitamin D3 (20 micrograms/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0 micrograms vitamin D3/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0 micrograms vitamin D3/day)
Study: NCT01956864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
Study: NCT04657562

Intervention type: DRUG
Intervention: Tacrolimus
Description: Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.
Study: NCT02637388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oatwell28 Oatwell Original Powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Breakfast
Description: Isocaloric breakfast without added beta-glucans
Study: NCT04657562

Intervention type: DRUG
Intervention: Tacrolimus
Description: Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.

Intervention type: DRUG
Intervention: Tacrolimus
Description: Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.

Intervention type: DIAGNOSTIC_TEST
Intervention: Unbound tacrolimus measurement
Description: Unbound tacrolimus measurement in plasma ultrafiltrate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Unbound tacrolimus measurement
Description: Unbound tacrolimus measurement in plasma ultrafiltrate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Unbound tacrolimus measurement
Description: Unbound tacrolimus measurement in plasma ultrafiltrate.

Intervention type: DIAGNOSTIC_TEST
Intervention: CYP3A4 and CYP3A5 genotyping
Description: DNA purification and genotyping

Intervention type: DIAGNOSTIC_TEST
Intervention: CYP3A4 and CYP3A5 genotyping
Description: DNA purification and genotyping

Intervention type: DIAGNOSTIC_TEST
Intervention: CYP3A4 and CYP3A5 genotyping
Description: DNA purification and genotyping
Study: NCT01411098

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT02892487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing therapy
Description: Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
Study: NCT04679103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab (JSC GENERIUM, Russia)
Description: Eculizumab
Study: NCT04808128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drink A + SC
Description: Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with simple carbohydrates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drink B + SC
Description: Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with simple carbohydrates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drink C + SC
Description: Consumption of soda water, non-caffeine and non-carbohydrate drink together with simple carbohydrates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drink A + CC
Description: Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with complex carbohydrates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drink B + CC
Description: Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with complex carbohydrates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drink C + CC
Description: Consumption of soda water, non-caffeine and non-carbohydrate drink together with complex carbohydrates.
Study: NCT03051126

Intervention type: OTHER
Intervention: Tissue Samples
Description: Fresh residual tissue samples will be obtained during parathyroid and/or pancreas tumor intervention (for pancreas tumor intervention in MEN1 patients with hyperparathyroidism and pancreatic lesions).
Study: NCT03941314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supera® Peripheral Stent System
Description: The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EverFlex™ Self-Expanding Peripheral Stent System
Description: The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
Study: NCT01170819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double balloon catheter
Description: The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 10 mg controlled-release vaginal insert
Description: Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
Study: NCT00819949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.